Your browser is no longer supported. Please, upgrade your browser.
PGNX Progenics Pharmaceuticals, Inc. daily Stock Chart
Progenics Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.90 Insider Own0.10% Shs Outstand90.22M Perf Week-20.43%
Market Cap333.81M Forward P/E- EPS next Y-0.17 Insider Trans0.00% Shs Float78.36M Perf Month-30.71%
Income-73.00M PEG- EPS next Q-0.17 Inst Own79.30% Short Float12.83% Perf Quarter-20.43%
Sales16.70M P/S19.99 EPS this Y-11.60% Inst Trans1.37% Short Ratio12.97 Perf Half Y-24.49%
Book/sh0.99 P/B3.74 EPS next Y73.40% ROA-41.10% Target Price9.58 Perf Year-52.75%
Cash/sh1.21 P/C3.05 EPS next 5Y- ROE-74.70% 52W Range3.54 - 8.11 Perf YTD-11.90%
Dividend- P/FCF- EPS past 5Y-2.60% ROI-44.40% 52W High-54.38% Beta2.72
Dividend %- Quick Ratio4.80 Sales past 5Y14.70% Gross Margin- 52W Low4.52% ATR0.28
Employees79 Current Ratio4.80 Sales Q/Q34.40% Oper. Margin- RSI (14)28.16 Volatility8.36% 5.76%
OptionableYes Debt/Eq0.52 EPS Q/Q-19.70% Profit Margin- Rel Volume0.99 Prev Close3.60
ShortableYes LT Debt/Eq0.45 EarningsAug 09 BMO Payout- Avg Volume775.21K Price3.70
Recom1.60 SMA20-23.55% SMA50-26.45% SMA200-22.74% Volume768,138 Change2.78%
Dec-07-18Initiated Credit Suisse Outperform $6.50
Sep-14-18Downgrade Needham Strong Buy → Buy $16 → $12
Aug-01-18Reiterated Needham Strong Buy $14 → $16
Feb-06-17Upgrade Needham Buy → Strong Buy $11 → $14
Oct-27-16Initiated Aegis Capital Buy
Oct-23-15Upgrade Jefferies Hold → Buy
Aug-07-15Reiterated Needham Buy $9 → $11
Aug-06-15Reiterated Brean Capital Buy $11 → $14
Feb-03-14Upgrade Needham Hold → Buy $8
Aug-30-12Initiated Stifel Nicolaus Hold
Jul-30-12Downgrade Needham Buy → Hold
Feb-10-11Upgrade Brean Murray Hold → Buy $13
Oct-14-09Downgrade Needham Buy → Hold
May-12-09Reiterated RBC Capital Mkts Outperform $14 → $12
Mar-16-09Reiterated RBC Capital Mkts Outperform $21 → $14
Mar-16-09Downgrade Oppenheimer Outperform → Perform
Mar-16-09Downgrade Brean Murray Buy → Hold
Mar-12-09Initiated FTN Equity Capital Neutral
Aug-11-08Reiterated RBC Capital Mkts Outperform $19 → $21
Jul-02-08Downgrade Friedman Billings Mkt Perform → Underperform $9 → $12
Aug-15-19 10:25AM  Edited Transcript of PGNX earnings conference call or presentation 9-Aug-19 12:30pm GMT Thomson Reuters StreetEvents -5.26%
Aug-12-19 08:00AM  Velan Highlights Progenics Pharmaceuticals' Continued Mismanagement Following Q2 2019 Earnings Results PR Newswire -16.13%
Aug-09-19 11:23PM  Progenics Pharmaceuticals (PGNX) Q2 2019 Earnings Call Transcript Motley Fool -6.06%
10:23AM  Could The Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Ownership Structure Tell Us Something Useful? Simply Wall St.
08:55AM  Progenics (PGNX) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM  Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update GlobeNewswire
Aug-08-19 08:00AM  Progenics Pharmaceuticals Announces Additional Governance Enhancements GlobeNewswire
Aug-06-19 08:30AM  CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131) GlobeNewswire
Aug-05-19 08:30AM  Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer GlobeNewswire
Aug-01-19 08:30AM  Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9 GlobeNewswire
Jul-25-19 08:30AM  Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis GlobeNewswire
Jul-22-19 08:00AM  Velan Announces Progenics Pharmaceuticals Stockholders Support its Campaign for Change at Progenics' 2019 Annual Meeting PR Newswire
Jul-17-19 07:41PM  Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets CNW Group
Jul-12-19 09:11AM  Progenics Announces Preliminary Voting Results of Annual Meeting of Shareholders GlobeNewswire
Jul-08-19 08:30AM  Progenics Urges Shareholders to Vote Today FOR the Highly Qualified Director Candidates on the WHITE Proxy Card GlobeNewswire
08:00AM  Velan Reminds Stockholders to Follow ISS' Recommendation by Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch PR Newswire
07:30AM  Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial GlobeNewswire
Jul-05-19 12:26PM  Heres What Hedge Funds Think About Progenics Pharmaceuticals, Inc. (PGNX) Insider Monkey
Jul-01-19 08:00AM  Velan Urges Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch PR Newswire
07:00AM  Leading Independent Proxy Advisory Firm Glass Lewis Recommends Progenics Shareholders Vote FOR ALL of Progenics Director Nominees GlobeNewswire
Jun-28-19 11:40AM  ISS Supports Velan's Call for Change by Recommending Stockholders Vote "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch PR Newswire +6.01%
10:30AM  Progenics Reiterates Targeted Directors Indispensable Experience and Leadership Critical to the Companys Long-Term Success GlobeNewswire
07:32AM  The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO Benzinga
12:01AM  Velan Clarifies Interactions with Progenics Pharmaceuticals' Board of Directors PR Newswire
Jun-27-19 09:00PM  Progenics Pharmaceuticals Details Recent Good Faith Efforts to Settle with Velan Capital GlobeNewswire +5.82%
Jun-25-19 08:30AM  Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer GlobeNewswire
08:29AM  Velan Releases Presentation Reiterating the Facts and Setting The Record Straight for Progenics Pharmaceuticals' Stockholders PR Newswire
Jun-24-19 08:30AM  Independent Readers Using Progenics PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI GlobeNewswire
08:00AM  Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velans Latest Inaccurate Claims GlobeNewswire
Jun-20-19 05:21PM  Velan Releases Detailed Presentation on Progenics Pharmaceuticals PR Newswire
08:30AM  Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors GlobeNewswire
07:30AM  Velan Calls on Progenics Pharmaceuticals' Board to Back Up Recent Claims PR Newswire
Jun-19-19 12:05PM  Did Changing Sentiment Drive Progenics Pharmaceuticals's (NASDAQ:PGNX) Share Price Down By 46%? Simply Wall St.
08:30AM  Progenics to Mail Letter to Shareholders GlobeNewswire
Jun-18-19 09:05AM  Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan GlobeNewswire +6.41%
Jun-17-19 08:30AM  Velan sets the Record Straight on Progenics Pharmaceuticals' Latest Misleading Statements PR Newswire +6.85%
Jun-13-19 05:00PM  Progenics to Mail Letter to Shareholders GlobeNewswire
08:30AM  Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer GlobeNewswire
Jun-11-19 08:30AM  Velan Capital Sends Letter to Stockholders Calling Out Progenics Pharmaceuticals' Board for Unnecessarily Diluting Stockholders to Support Outsized And Undeserved Compensation PR Newswire
Jun-06-19 07:45AM  Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting GlobeNewswire
Jun-04-19 08:30AM  Velan Responds to Progenics Pharmaceuticals' Misleading Statements PR Newswire +6.85%
Jun-03-19 08:30AM  Progenics Announces Updated Survival Data for AZEDRA® (iobenguane I 131) in Advanced Pheochromocytoma and Paraganglioma GlobeNewswire
08:00AM  Progenics Pharmaceuticals Mails Letter to Shareholders GlobeNewswire
May-30-19 08:30AM  Progenics Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-23-19 08:30AM  Progenics Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting GlobeNewswire
May-22-19 08:30AM  Velan Files Definitive Proxy Materials in Connection with Progenics Pharmaceuticals 2019 Annual Meeting of Stockholders PR Newswire
May-19-19 11:59PM  Edited Transcript of PGNX earnings conference call or presentation 9-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-14-19 08:30AM  Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404 GlobeNewswire
May-13-19 08:30AM  Velan Implores for Improved Transparency and Real Change at Progenics Pharmaceuticals Following Q1 2019 Earnings Call PR Newswire -5.50%
May-10-19 02:24PM  Progenics Pharmaceuticals (PGNX) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 09:05AM  Progenics (PGNX) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:53AM  Progenics: 1Q Earnings Snapshot Associated Press
07:45AM  Progenics Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update GlobeNewswire
May-08-19 02:30PM  Velan Calls for Increased Transparency at Progenics Pharmaceuticals During Q1 Earnings Call PR Newswire
May-07-19 04:15PM  Progenics Pharmaceuticals Comments on Velan Capitals Preliminary Proxy Statement GlobeNewswire
May-06-19 04:15PM  Progenics Pharmaceuticals Issues Statement Regarding Velan Capital GlobeNewswire
08:30AM  Velan Delivers Letter to the Board of Progenics Pharmaceuticals PR Newswire
08:30AM  Data Presented at the 2019 American Urological Association (AUA) Annual Meeting Showcases Potential for Progenics PyL Imaging Agent GlobeNewswire
May-02-19 08:30AM  Progenics Pharmaceuticals Sets First Quarter 2019 Financial Results and Business Update Call for May 9 GlobeNewswire
May-01-19 10:32AM  Earnings Preview: Progenics (PGNX) Q1 Earnings Expected to Decline Zacks
Apr-24-19 08:30AM  Results from Clinical Trial Show Progenics PyL (18F-DCFPyL) PSMA PET/CT Imaging Agent Changes Management Plans for More Than 87% of Patients GlobeNewswire
Apr-12-19 08:00PM  Investor Altiva Wants to Repopulate Progenics Board
08:41AM  These 3 Biotech Stocks Are Moving Closer to Profitability
Apr-11-19 08:17AM  How Many Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Shares Did Insiders Buy, In The Last Year? Simply Wall St. +8.53%
Apr-03-19 05:05PM  Progenics Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference GlobeNewswire
05:00PM  Progenics Pharmaceuticals Announces Presentations at the 2019 American Urological Association (AUA) Annual Meeting GlobeNewswire
Mar-18-19 12:26PM  Edited Transcript of PGNX earnings conference call or presentation 14-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
10:00AM  My Post-Earnings Assessment of 2 Biotech Stocks
Mar-14-19 09:10AM  Progenics (PGNX) Reports Q4 Loss, Misses Revenue Estimates Zacks
08:18AM  Progenics: 4Q Earnings Snapshot Associated Press
07:47AM  The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering Benzinga
07:45AM  Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2018 Financial Results and Business Update GlobeNewswire
07:40AM  Progenics Asserts Ownership of PSMA-617 Intellectual Property, Including Composition of Matter Patent GlobeNewswire
Mar-11-19 08:30AM  Progenics Pharmaceuticals Announces Presentation of Safety Data for AZEDRA® (iobenguane I 131) at the 2019 Endocrine Society (ENDO) Annual Meeting GlobeNewswire
Mar-07-19 08:30AM  Progenics Pharmaceuticals Sets Fourth Quarter and Full-Year 2018 Financial Results and Business Update Call for March 14 GlobeNewswire
Feb-20-19 09:12AM  3 Small Biotechs to Watch as Earnings Season Winds Down
Feb-11-19 08:30AM  Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility GlobeNewswire
Jan-22-19 07:45AM  Market Trends Toward New Normal in Agilent Technologies, Xilinx, Interpublic Group of Companies, Progenics Pharmaceuticals, Flexsteel Industries, and USA Truck Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-03-19 04:45PM  Steven Cohen Storms Into Progenics Pharmaceuticals
01:30AM  Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL GlobeNewswire
Jan-02-19 08:30AM  Progenics Pharmaceuticals Expands Leadership Team with Appointment of Asha Das, M.D. as Chief Medical Officer GlobeNewswire
Dec-12-18 09:06AM  Here Are 3 Small-Cap Names for Biotech Investors to Consider +5.96%
Dec-11-18 02:35PM  What Did Progenics Pharmaceuticals, Inc.s (NASDAQ:PGNX) CEO Take Home Last Year? Simply Wall St. +8.29%
Dec-08-18 07:50PM  Should You Buy NanoString Technologies Inc (NSTG)? Insider Monkey
Dec-05-18 05:09PM  Is Noodles & Co (NDLS) A Good Stock To Buy? Insider Monkey
Dec-03-18 08:30AM  Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer GlobeNewswire
Nov-28-18 07:30AM  Research Report Identifies Capstone Turbine, LivePerson, Diamondback Energy, Presidio, Pretium Resources, and Progenics Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-19-18 04:30PM  Progenics Pharmaceuticals Announces Presentation of Updated Safety and Tolerability Data for AZEDRA® (iobenguane I 131) at the Radiological Society of North America (RSNA) Annual Meeting GlobeNewswire
Nov-08-18 05:38PM  Edited Transcript of PGNX earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
09:55AM  Progenics (PGNX) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:49AM  Progenics: 3Q Earnings Snapshot Associated Press
07:30AM  Progenics Pharmaceuticals Announces Third Quarter 2018 Financial Results And Business Update GlobeNewswire
Nov-06-18 08:00AM  Progenics Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Nov-01-18 08:00AM  Progenics Pharmaceuticals Sets Third Quarter 2018 Financial Results and Business Update Call for November 8 GlobeNewswire
Oct-18-18 08:25AM  Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +5.48%
Oct-12-18 07:34AM  The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program Benzinga
Oct-11-18 04:01PM  Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA GlobeNewswire
Oct-09-18 08:30AM  Progenics Announces Publication of Pivotal Trial of AZEDRA® (iobenguane I 131) in The Journal of Nuclear Medicine GlobeNewswire
Oct-08-18 06:28PM  Generic-Drugs Stock Outlook: No Respite from Pricing Issues Zacks
Oct-05-18 09:52AM  Progenics On Positive Prostate Cancer Imaging Data: 'These Are Highly Encouraging Results' Benzinga
Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Campbell Bradley LDirectorJul 03Option Exercise4.8912,00058,68012,000Jul 08 12:32 PM
SCHEINBERG DAVID ADirectorJul 01Option Exercise5.3310,00053,30056,185Jul 03 08:56 AM
Crowley Peter JDirectorJun 26Option Exercise5.3550,000267,30050,000Jun 27 04:33 PM